UK markets close in 20 minutes

Hikma Pharmaceuticals PLC (HKMPY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
50.280.00 (0.00%)
As of 03:17PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close50.28
Bid0.00 x 0
Ask0.00 x 0
Day's range50.28 - 50.28
52-week range40.72 - 56.63
Avg. volume385
Market cap5.581B
Beta (5Y monthly)0.45
PE ratio (TTM)29.58
Earnings dateN/A
Forward dividend & yield1.24 (2.47%)
Ex-dividend date11 Aug 2023
1y target estN/A
  • Reuters

    Merck's Bridion faces generic threat from drugmaker Hikma

    Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.


    £9,000 in excess savings? I’d buy 457 shares of this dividend stock to target a £1,100 extra income

    Dividend stocks that consistently boost payouts can offer investors massive yields long term. Here’s a share that may be on track to do just that. The post £9,000 in excess savings? I’d buy 457 shares of this dividend stock to target a £1,100 extra income appeared first on The Motley Fool UK.

  • Reuters

    High-dose opioid reversal spray no better than lower dose in field, US study finds

    A high-dose version of the opioid reversal spray naloxone, made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement, according to a U.S. study. The analysis also suggests that those given the higher 8 milligram strength spray were more than twice as likely to experience opioid withdrawal symptoms compared to other sprays such as Narcan that use a 4 mg dose. The Hikma version, sold under the brand name Kloxxado, was approved in 2021 after U.S. Food and Drug Administration advisers and National Institutes of Health reports suggested that a high-dose version was needed to respond to overdoses by more potent opioids such as fentanyl.